繁體中文
Company history

Company History

Sep-82

Syn-Tech established

Nov-82

Registration capital NTD12 million.

Nov-83

Plant A and B were constructed and approved by the Health bureau for producing API.

Jun-87

Increased capital to NTD18 million

Dec-88

Plant C were constructed, new product was launched.

Aug-89

Capital increased to NTD30 million.

Jun-90

Major office, QC and RD building was constructed.

Mar-91

Plant D and raw material warehouse was expanded.

 

API GMP plant B was finished re-construction.

Jul-91

Capital increased to NTD60 million.

 

Land size expanded to 12,852 square meters.

Aug-93

Large scale waste water treatment facility was established

 

GMP plant E , Large scale waste gas treatment were established.

Mar-94

Chlorzoxazone  and diclofenac sodium filed US DMF.

Aug-94

The plants and facilities filed DMF 11038.

Mar-95

Capital increased to NTD100 million.

Mar-95

Chlorzoxazone audited by US FDA and approved.

May-96

Diclofenac sodium approved by Canadian Health bureau.

 

Filed Diclofenac sodium USDMF No.9643.

Feb-97

Chlorzoxazone was filed to sweden, Finland and Denmark. The DMF NO.J. NO. 5216-279-1997

Aug-97

Plant A pilot area was finished.

Sep-97

Filed Diclofenac potassium USDMF No.12656 and Canadian H.P.B. 9783.

Oct-97

 Increased capital to 150 million.

Oct-98

Approved by ISO9001

Mar-99

Chlorzoxazone, Diclofenac sodium, Diclofenac potassium passed the US FDA inspection.

Jun-99

Plant D complied with GMP.

Aug-00

Approved by ISO14001

Nov-02

First API manufacturer in Taiwan passed GMP.

Dec-02

Approved by OHSAS 18001.

Dec-02

Awarded by the DOH for approval cGMP inspection 

Oct-05

Capital increased to NTD216 million.

Oct-05

Listed on the stock exchange market  as a public company.

Dec-06

Chlorzoxazone awarded by the National quality prize.

Mar-07

Awarded by the National authority for "Clean neighborhood award"

Apr-07

Approved by the DOH cGMP post-inspection.

Sep-07

Phenylephrine HCL Approved by  cGMP inspection.

Oct-07

Awarded by the Minister of economic affair for " Standardized prize." 

Oct-07

Passed the KFDA on site inspection.

Feb-08

Passed the US FDA third time on site inspection.

Jun-08

Passed the Hungarian HNIP on site inspection.

May-09

Approved by the DOH cGMP post-inspection.

Aug-09

Capital increased to NTD238 million.

Dec-09

Awarded by the DOH for the "Awards of Medicine R&D".

Jun-11

Awarded by the Minister of economic affair for " Innovation awards". 

Jul-11

Diclofenac diethylamine, Orciprenaline, Metaxalone passed the  cGMP inspection by DOH Taiwan.

Apr-12

Passed the forth times US FDA inspection with no form 483 issued.

Aug-12

Capital increased to NTD250 million.